CAJ | 학술논문

目的探讨组蛋白去乙酰化酶2(HDAC2)在星形细胞瘤中的表达及其临床意义.方法收集283例WHO Ⅱ～Ⅳ级原发性星型细胞瘤标本和52例复发病例肿瘤标本,其中Ⅱ级59例,Ⅲ级26例,Ⅳ级250例.运用免疫组织化学和免疫荧光法探讨HDAC2在星型细胞瘤中的表达和分布.提取肿瘤组织、肿瘤干细胞和胶质瘤细胞株细胞RNA进行半定量逆转录-聚合酶链反应(RT-PCR)分析HDAC2表达水平.结果约85.6％的肿瘤细胞核阳性表达HDAC2,大约33.5％的肿瘤中有超过75.0％的肿瘤细胞阳性表达HDAC2.在10组WHO病理级别升高的标本中,可见HDAC2的表达强度在1例中减弱,在7例中增强,在其他2例中的差异无统计学意义(P＞0.05).在23组WHO病理级别无差异的复发肿瘤标本中,可见HDAC2的表达强度在6例中减弱,在10例中增强,在其他7例中差异无统计学意义(p＞0.05).HDAC2仅仅表达于肿瘤细胞,内皮细胞和小胶质细胞都没有HDAC2的表达.HDAC2的表达与细胞核增殖抗原(Ki-67)的表达密切相关(P＜0.01).在WHOⅣ级病例中,HDAC2的表达与患者预后临界相关[风险比(HR)=0.7343,95％可信区间(CI)(0.5252～1.0470)；P＞0.05].低于75.0％瘤细胞HDAC2表达的病例的中位生存时间为425 d,远远高于超过75.0％瘤细胞表达HDAC2的病例的350 d.结论 HDAC2在星形细胞瘤细胞增殖中发挥了重要作用.
목적 탐토조단백거을선화매2(HDAC2)재성형세포류중적표체급기림상의의.방법 수집283례WHO Ⅱ～Ⅳ급원발성성형세포류표본화52례복발병례종류표본,기중Ⅱ급59례,Ⅲ급26례,Ⅳ급250례.운용면역조직화학화면역형광법탐토HDAC2재성형세포류중적표체화분포.제취종류조직、종류간세포화효질류세포주세포RNA진행반정량역전록-취합매련반응(RT-PCR)분석HDAC2표체수평.결과 약85.6％적종류세포핵양성표체HDAC2,대약33.5％적종류중유초과75.0％적종류세포양성표체HDAC2.재10조WHO병리급별승고적표본중,가견HDAC2적표체강도재1례중감약,재7례중증강,재기타2례중적차이무통계학의의(P＞0.05).재23조WHO병리급별무차이적복발종류표본중,가견HDAC2적표체강도재6례중감약,재10례중증강,재기타7례중차이무통계학의의(p＞0.05).HDAC2부부표체우종류세포,내피세포화소효질세포도몰유HDAC2적표체.HDAC2적표체여세포핵증식항원(Ki-67)적표체밀절상관(P＜0.01).재WHOⅣ급병례중,HDAC2적표체여환자예후림계상관[풍험비(HR)=0.7343,95％가신구간(CI)(0.5252～1.0470)；P＞0.05].저우75.0％류세포HDAC2표체적병례적중위생존시간위425 d,원원고우초과75.0％류세포표체HDAC2적병례적350 d.결론 HDAC2재성형세포류세포증식중발휘료중요작용.
Objective To investigate the expression and significance of histone deacetylase 2 (HDAC2) in astrocvtomas.Methods Samples from 283 cases of primary gliomas with WHO Ⅱ-Ⅳ and 52 eases of recurrent tumors were collected.Histopathologically,there were 59 cases of low-grade gliomas (grade Ⅱ) and 276 cases of high-grade gliomas (26 cases of grade Ⅲ and 250 cases of glioblastomas).The expression of HDAC1 was immunohistochemicallv detected and its correlation with tumor differentiation,tumor proliferation and survival was analyzed.Results Totally,85.6％ of the tumors showed nuclear expression,and about 33.5％ of them showed more than 75.0％ nuclear expression.In these individuals who underwent tumor relapse with increasing in WHO grade,10 of them could be evaluated after stainning procedure.The immunoreactivity was decreased with tumor progression only in 1 case,remained stable immunoreactivity in 2 cases,and increased in 7 cases.In these individuals who underwent tumor relapse without increasing in WHO grade,23 of them could be evaluated,and HDAC2 immunoreactivitv was decreased in 6 cases,remained stable in 7 cases and increased in the other 10 cases.HDAC2 was not expressed in endothelial or microglia cells,and only expressed in tumor cells.There was significant association between HDAC2 and proliferation cell nuclear antigen (Ki-67) expression.In WHO grade Ⅳ subgroup,HDAC2 expression showed a horderline significance with shortened overall survival [hazard ratio (HR) =0.7343,95 ％ confidence interval (CI) (0.5152 to 1.0470) ; P ＞ 0.05].And the median survival in GBM patients with less than 75.0％ nuclear HDAC2 expression was 425 days as compared to 350 days in GBM patients with more nuclear HDAC2 expression.Conclusion There was a significant association between HDAC2 expression and astrocytoma proliferation.